Can you provide the last earnings date for ImmunoGen Inc?
ImmunoGen Inc (IMGN) last reported earnings on 2/9/2024.
NASDAQ:IMGN • US45253H1014
Past quarterly earnings results for ImmunoGen Inc (IMGN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2023 | 0.10 | 0.05 | 119.72% | 132.26% | 113.4M | 108.54M | 4.48% | 636.36% |
| Q2 2023 | -0.02 | -0.14 | 85.91% | 91.67% | 83.2M | 49.316M | 68.71% | 485.92% |
| Q1 2023 | -0.16 | -0.25 | 37.05% | -60.00% | 49.9M | 20.881M | 138.97% | 30.97% |
| Q4 2022 | -0.23 | -0.30 | 23.99% | -35.29% | 41.2M | 17.597M | 134.13% | 47.14% |
| Q3 2022 | -0.31 | -0.26 | -19.40% | -72.22% | 15.4M | 12.725M | 21.02% | 67.39% |
| Q2 2022 | -0.24 | -0.22 | -10.99% | -60.00% | 14.2M | 16.499M | -13.93% | -15.98% |
| Q1 2022 | -0.10 | -0.22 | 53.54% | 41.18% | 38.1M | 21.903M | 73.95% | 142.68% |
| Q4 2021 | -0.17 | -1.74 | 90.24% | -206.25% | 28M | 26.162M | 7.03% | -67.37% |
| Q3 2021 | -0.18 | -0.19 | 4.32% | -38.46% | 9.2M | 19.408M | -52.60% | -49.45% |
| Q2 2021 | -0.15 | -0.19 | 19.30% | -7.14% | 16.9M | 19.3M | -12.44% | 12.67% |
| Q1 2021 | -0.17 | -0.19 | 11.11% | - | 15.7M | 18.082M | -13.17% | 18.05% |
| Q4 2020 | 0.16 | -0.08 | 293.66% | - | 85.8M | 41.644M | 106.03% | - |
| Q3 2020 | -0.13 | -0.18 | 29.59% | - | 18.2M | 15.665M | 16.18% | - |
| Q2 2020 | -0.14 | -0.17 | 18.94% | - | 15M | 14.883M | 0.79% | - |
| Q1 2020 | -0.17 | -0.16 | -8.70% | - | 13.3M | 15.241M | -12.74% | - |
Notes
ImmunoGen Inc (IMGN) last reported earnings on 2/9/2024.
ImmunoGen Inc (IMGN) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, ImmunoGen Inc (IMGN) has beaten EPS estimates in 4 out of 4 releases.